## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

ONB APPROVAL												
OMB Number:	3235-0287											
Estimated average burde	en											
hours per response:	0.5											

I

			2. Issuer Name and Ticker or Trading Symbol <u>Adaptive Biotechnologies Corp</u> [ ADPT ]		tionship of Reporting Pe all applicable)	( )
(Last)	(First) VE BIOTECHN	(Middle) OLOGIES	3. Date of Earliest Transaction (Month/Day/Year) 09/16/2020		Director Officer (give title below) CEO and Ch	10% Owner Other (specify below) airman
1551 EASTLAKE AVE E STE 200			4. If Amendment, Date of Original Filed (Month/Day/Year)		vidual or Joint/Group Filir	ng (Check Applicable
(Street) SEATTLE	WA	98102		Line) X	Form filed by One Re Form filed by More the Person	, ,
(City)	(State)	(Zip)				

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock	09/16/2020		M <sup>(1)</sup>		16,680	A	\$0.33	1,794,860	D	
Common Stock	09/16/2020		<b>S</b> <sup>(1)</sup>		6,180	D	<b>\$</b> 45.47 <sup>(2)</sup>	1,788,680	D	
Common Stock	09/16/2020		<b>S</b> <sup>(1)</sup>		5,000	D	\$46.45 <sup>(3)</sup>	1,738,680	D	
Common Stock	09/16/2020		<b>S</b> <sup>(1)</sup>		5,100	D	<b>\$</b> 47.46 <sup>(4)</sup>	1,778,580	D	
Common Stock	09/16/2020		<b>S</b> <sup>(1)</sup>		400	D	\$48.26 <sup>(5)</sup>	1,778,180	D	
Common Stock	09/17/2020		M <sup>(1)</sup>		16,680	A	\$0.33	1,794,860	D	
Common Stock	09/17/2020		<b>S</b> <sup>(1)</sup>		2,600	D	\$44.48(6)	1,792,260	D	
Common Stock	09/17/2020		<b>S</b> <sup>(1)</sup>		14,080	D	\$45.26 <sup>(7)</sup>	1,778,180	D	
Common Stock	09/18/2020		M <sup>(1)</sup>		16,680	A	\$0.33	1,794,860	D	
Common Stock	09/18/2020		<b>S</b> <sup>(1)</sup>		8,100	D	\$45.28(8)	1,786,760	D	
Common Stock	09/18/2020		<b>S</b> <sup>(1)</sup>		8,580	D	\$46.13(9)	1,778,180	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$0.33	09/16/2020		<b>M</b> <sup>(1)</sup>			16,680	(10)	12/20/2021	Common Stock	16,680	\$0.00	228,000	D	
Stock Option (Right to Buy)	\$0.33	09/17/2020		M <sup>(1)</sup>			16,680	(10)	12/20/2021	Common Stock	16,680	\$0.00	211,320	D	
Stock Option (Right to Buy)	\$0.33	09/18/2020		M <sup>(1)</sup>			16,680	(10)	12/20/2021	Common Stock	16,680	\$0.00	194,640	D	

## Explanation of Responses:

1. These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$45.08 to 46.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$46.11 to 47.07, inclusive.

4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$47.18 to 48.14, inclusive.

5. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$48.26 to 48.27, inclusive.

6. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$44.35 to 44.57, inclusive.

7. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$44.58 to 45.57, inclusive.

8. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$44.79 to 45.74, inclusive.

9. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$45.80 to 46.55, inclusive. 10. The options are fully vested and exercisable.

Remarks:

/s/ Chad M. Robins by Eric Billings, Attorney-in-Fact \*\* Signature of Reporting Person

09/18/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.